Get the Stockscreener App
1.09
0.93%
0.01
After Hours:
1.09
Cardiff Oncology Inc stock is traded at $1.09, with a volume of 437.28K.
It is up +0.93% in the last 24 hours and up +17.34% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$1.08
Open:
$1.08
24h Volume:
437.28K
Relative Volume:
0.34
Market Cap:
$84.80M
Revenue:
$525.00K
Net Income/Loss:
$-44.76M
P/E Ratio:
-1.6386
EPS:
-0.6652
Net Cash Flow:
$-37.46M
1W Performance:
+15.96%
1M Performance:
+17.34%
6M Performance:
-44.95%
1Y Performance:
-48.83%
1-Day Range:
$1.065
$1.10
1-Week Range:
$0.9026
$1.10
52-Week Range:
$0.7566
$3.31
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.09 | 70.69M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Cardiff Oncology Announces Upcoming Conference Participation for Mani Mohindru, Ph.D. - Quiver Quantitative
Cardiff Oncology will take part in two September cancer conferences - Stock Titan
Cardiff Oncology Inc. (CRDF) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Cardiff Oncology Inc. (CRDF) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Equities Analysts Offer Predictions for CRDF Q3 Earnings - MarketBeat
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - vinanet.vn
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
William Blair downgrades Cardiff Oncology (CRDF) to a Hold - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRDF Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D BurnRevenue Guidance Update - vinanet.vn
Cardiff Oncology (CRDF) Holds at $0.85 After Modest Gain; Key Resistance at $0.89 in FocusScalping Stock Signals - vinanet.vn
BlackRock, Inc. Slashes Cardiff Oncology (CRDF) Stake by 78.3% - GuruFocus
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A - Stock Titan
CRDF|Cardiff Oncology Inc|Price:0.952|Chg%:+0.023 - TradingKey
Cardiff Oncology Inc (CRDF) Balance Sheet - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011 - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF - TradingView
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc (CRDF) Cash Flow - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.831|Chg%:+0.004 - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.845| - TradingKey
TradingKey - TradingKey
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
CRDF Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Pipeline DevelopmentEarnings Yield Spread - vinanet.vn
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer |
Jul 14 '26 |
Buy |
1.46 |
34,364 |
50,000 |
59,067 |
| Mohindru Mani | Chief Executive Officer |
Jun 18 '26 |
Buy |
1.21 |
24,703 |
29,891 |
24,703 |
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):